How can BioScrip Inc. (NASDAQ:BIOS) impact your portfolio?


Let us have a close look at BioScrip Inc. (NASDAQ:BIOS) today to get a better perspective of the company and its prevailing status, as well as the opportunity it may present for prospective investors. Today’s emphasis will be a fundamental assessment of the stock. So, let’s start this analysis with the top line: Revenue trends.

The company witnessed its sales move to $217.81M in total revenues. That shows change in revenues, on a quarterly YoY basis, of -0.09%. In sequential terms, the firm saw sales decline by -0.1% from quarter to quarter.

The cost of selling goods for BioScrip Inc. (NASDAQ:BIOS) in last quarter was $159.21M, yielding a gross income of $58.6M. For shareholders, given the total diluted due shares of 118.78M, this means earnings per share of $(0.18). Note, this compares with an analyst forecast of $-0.06 in earnings per share for its imminent fiscal quarterly report.

At present, analysts provided a consensus average recommendation of Buy based on a total of 6.

Analysts have an average target of $2.75 on the stock. For next year fiscal year forecast is about $-0.17 in EPS. On a median price/earnings ratio basis, the valuation is 9,999 times earnings.

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is in highly overbought territory. Beware of a trend reversal.

For BioScrip Inc. (NASDAQ:BIOS), the firm presently holds about $21.1M in cash in the reserves. That cash is balanced against approximately $22.43M in total current liabilities.

The firm’s debt has been $falling. It also has $602.42M in total assets, balanced by $575.88M in total liabilities.

The company recorded a free cash flow last quarter of $(12.72M), representing a quarterly net change of $11.53M. On a net operating level, the firm saw about $(11.03M) in cash flow.

We will bring up-to-date the interesting story of BioScrip Inc. (NASDAQ:BIOS) as new events transpire.